Leerink Partners Maintains Outperform on Merck & Co, Raises Price Target to $161

Benzinga Newsdesk www.benzinga.com Positive 91.5%

Neg 0% Neu 0% Pos 91.5%

Leerink Partners analyst Daina Graybosch maintains Merck & Co (NYSE:MRK) with a Outperform and raises the price target from $127 to $161.